JOURNAL ARTICLE
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
Year: 2019 Journal: Case Medical Research Publisher: Case Journals
Keywords:
Daunorubicin Cytarabine Myeloid leukemia Medicine Leukemia Oncology Pharmacology Internal medicine
Metrics
0
Cited By
0.00
FWCI (Field Weighted Citation Impact)
0
Refs
0.34
Citation Normalized Percentile
Is in top 1%
Is in top 10%
Topics
Acute Myeloid Leukemia Research
Health Sciences → Medicine → Hematology
Chronic Myeloid Leukemia Treatments
Health Sciences → Medicine → Hematology
Histone Deacetylase Inhibitors Research
Life Sciences → Biochemistry, Genetics and Molecular Biology → Molecular Biology
Related Documents
JOURNAL ARTICLE
Liposomal cytarabine and daunorubicin (CPX-351) for treatment of acute myeloid leukemia
Aaron RonsonAriella TvitoJacob M. Rowe
Journal: Expert Opinion on Orphan Drugs Year: 2016 Vol: 5 (4)Pages: 369-374
JOURNAL ARTICLE
Cost-Effectiveness of Liposomal Cytarabine-Daunorubicin (CPX-351) Compared to Conventional Cytarabine-Daunorubicin Chemotherapy in Acute Myeloid Leukemia
Jan Philipp BewersdorfGeorge GoshuaKishan PatelRory M. ShallisNikolai A. PodoltsevScott F. HuntingtonAmer M. Zeidan
Journal: Blood Year: 2021 Vol: 138 (Supplement 1)Pages: 113-113
JOURNAL ARTICLE
Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia
Hannah AsghariJeffrey E. Lancet
Journal: Leukemia & lymphoma/Leukemia and lymphoma Year: 2020 Vol: 61 (6)Pages: 1305-1312
JOURNAL ARTICLE
Randomized Study of Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults with Untreated High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) at High Risk of Treatment-Related Mortality
Roland B. WalterKaysey F. OrlowskiMorgan A. PowellPamela S. BeckerPaul C. HendrieFabiana OstronoffElizabeth M. RankerMegan OthusArthur C. LouieElihu H. Estey
Journal: Blood Year: 2014 Vol: 124 (21)Pages: 994-994
JOURNAL ARTICLE
Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia
Lydia L. BenitezAnthony J. PerissinottiCaitlin R. RauschJeff KlausStephen M. ClarkMichael FiltzKelley L. RatermannCarissa TreptowShawn P. GriffinMarissa OlsonMallory CrainTapan M. KadiaKristen PettitPatrick W. BurkeDale L. BixbyBernard L. Marini
Journal: Leukemia & lymphoma/Leukemia and lymphoma Year: 2021 Vol: 62 (9)Pages: 2184-2192